Please login to the form below

Not currently logged in
Email:
Password:

William Humphries joins board of Clearside Biomedical

New CEO of Merz Pharma’s US operations joins the eyecare firm's board

Clearside Biomedical has appointed CEO of Merz Pharma's North American operations, William Humphries, to its board of directors.

Humphries joins the US-based firm, which specialises in developing eyecare products, just two weeks after his appointment at Merz Inc.

Clearside will be keen to make use of Humphries' 25 years' experience in the pharma industry as it looks to develop its microinjection platform to develop therapeutics for sight threatening conditions such as macular oedema and vascular leakage.

Prior to his appointment at Merz, Humphries was president of the GlaxoSmithKline company Stiefel, which specialises in dermatology.

Humphries has also held senior executive roles at Allergan, including VP of its US skincare business.

"Having served under Bill at Stiefel, I know firsthand how talented he is in the global commercialisation of products in today's healthcare environment and his experience is already providing an important impact to Clearside Biomedical," said Daniel White, Clearside's president and CEO.

"Bill brings a complementary vision to our company and a wealth of knowledge to the table that will help guide our company to achieving its goal of providing valuable medical solutions for patients suffering from sight-threatening illness."

4th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...

Infographics